• Six clinical trials on MSCs approved by US FDA
    Six clinical trials on MSCs approved by US FDA
  • One of the few companies manufacturing both hMSC and hNSC
    One of the few companies manufacturing both hMSC and hNSC
  • First FDA-approved clinical trial using stem cells to treat Alzheimer’s
    First FDA-approved clinical trial using stem cells to treat Alzheimer’s
  • MSCs approved as a treatment of AMI in Kazakhstan
    MSCs approved as a treatment of AMI in Kazakhstan
  • Producing clinical-grade stem cells with strong activity in large scale
    Producing clinical-grade stem cells with strong activity in large scale
  • SCF activity preserved through patented technology for 3 years
    SCF activity preserved through patented technology for 3 years

Add:21st Floor, Block 1, Jusha Center, No.16 Xinyuanli, Chaoyang District, Beijing

Phone: 86-10-64654791

 

 

Copyright ©Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.! 

京ICP备19006400号-1     Powered by 300.cn

About Us



Dr. Lev Verkh

没有此类产品
Details
 
 
 

Dr. Verkh has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, neurology, peripheral vascular diseases, hematology, blood disorders and imaging methods. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. Under his leadership, Stemedica obtained several INDs for clinical trials in the United States and emergency INDs from the FDA.

 
 

Dr. Lev Verkh

On a
Dr. Alex Kharazi